Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time they sign the consent form
• People who have been newly diagnosed with a confirmed advanced-stage ovarian, fallopian tube, or peritoneal cancer (specifically FIGO stage III or IV, high-grade serous or high-grade endometrioid type)
• People who have had primary or interval debulking surgery (surgery to remove as much of the tumour as possible), where either no visible tumour remained or the remaining tumour pieces were smaller than 1 cm
• People whose BRCA gene mutation status is already known, or whose BRCA test results will be available before the trial assignment takes place
• People whose blood test results meet the required levels for white blood cells, infection-fighting cells (neutrophils), red blood cells (haemoglobin), platelets, liver function, kidney function, and blood clotting (confirm specific values with the trial site)
• People with an overall health and activity level rated as ECOG 0, 1, or 2 — meaning someone who is fully active, has some limits on strenuous activity, or is able to care for themselves but unable to work (confirm with trial site)
• People who are able and willing to use two highly effective forms of contraception from signing the consent form until 6 months after the last dose of chemotherapy or the trial treatment (whichever comes later), with specific approved combinations required (confirm accepted combinations with trial site)
• People who are able to understand the consent form and are willing to sign it

Who may not be able to join:

• People whose ovarian cancer is not the epithelial type, or whose tumour has a mixed tissue type
• People diagnosed with borderline ovarian tumours (also called tumours of low malignant potential), which are a less aggressive type
• People who have already started platinum-based chemotherapy after surgery before joining the trial
• People whose treatment plan includes chemotherapy delivered directly into the abdomen (called intraperitoneal chemotherapy)
• People who have previously had, or are currently receiving, radiation therapy to the abdomen or pelvis
• People who have had major surgery (other than the debulking surgery for their cancer) within 3 weeks before signing the consent form, or who have not yet fully recovered from major surgery
• People who have had another type of cancer, unless that cancer has been in complete remission for at least 3 years — exceptions may apply for certain skin cancers or cervical carcinoma in situ that have been fully treated (confirm with trial site)
• People who have previously received immunotherapy treatments such as checkpoint inhibitors, therapeutic vaccines, cell-based therapies, or cytokine treatments (confirm with trial site if uncertain)
• People with active, uncontrolled spread of cancer to the brain or the lining around the brain or spinal cord — people with treated, stable spinal cord compression for at least 28 days may be considered (confirm with trial site)
• People who are HIV positive
• People with active hepatitis B, hepatitis C, or active syphilis
• People with an active bacterial, viral, or fungal infection that requires systemic (whole-body) treatment
• People with significant heart conditions, including uncontrolled heart failure, unstable chest pain, serious heart rhythm problems requiring medication, uncontrolled high blood pressure, or a history of heart attack, serious heart rhythm problems, or stroke within the past 6 months, or with very low heart pumping function (confirm specific thresholds with trial site)
• People with fluid around the heart (pericardial effusion) of any severity
• People with severe chronic lung disease classified as Grade C or D under international lung disease guidelines (confirm with trial site)
• People with other serious, uncontrolled medical conditions that the treating doctor considers too risky for participation
• People with a medical history or current condition that could interfere with the trial results or with completing the full course of treatment, or where participation is not considered in the person's best interest
• People with an active autoimmune disease that requires treatment
• People with a history of severe primary immune deficiency conditions
• People with a history of severe allergic reactions (including anaphylaxis) to vaccines
• People with psychiatric or social circumstances that, in the investigator's opinion, would prevent safe or full participation in the trial
• People with a known allergy or sensitivity to any ingredient in the trial treatment
• People receiving systemic immune-suppressing medications — short-term or low-dose steroids and inhaled or nasal steroids may be acceptable (confirm with trial site)
• People who have taken part in another clinical trial using an experimental treatment within the 4 weeks before signing the consent form
• People who are pregnant, breastfeeding, or planning to have children during the trial treatment period
• People who do not wish to sign the informed consent form

Important: Always verify eligibility with the trial site directly before applying.